These tables are the outcome of the authors�� personal

These tables are the outcome of the authors�� personal customer review endeavor to compile in a detailed, yet easy to refer way, information that has often been overlooked by the plethora of similar reviews and/or info on contentious issues in capsule enteroscopy. We believe that this document can be used as reference for study, in reference lists of future manuscript and as important guide for future clinical research on the field. INTRODUCTION An early conceptual abstract on capsule endoscopy (CE), entitled ��an endorobot for flexible endoscopy, a feasibility study��, was published in 1994[1]. Then, in 1997 two groups of pioneers, initially working independently in Israel and London, joined forces to achieve wireless endoscope[2].

Three years later, in the Digestive Disease Week meeting of the millennium and almost concurrently in Nature[3], Professor Swain presented the world��s first wireless capsule endoscope. Indeed, the brainchild of Iddan[4] has revolutionised the field of gastrointestinal (GI) diagnostics, turning into reality the concept of painless and wireless endoscopy. Furthermore, the introduction of CE in clinical practice increased the interest for the study of the small-bowel. Consequently, in about 10 years, an impressive quantity of literature on indications, diagnostic yield (DY), safety profile and technical evolution of CE has been published as well as several reviews. Therefore, we aim to focus readers�� attention on contemporary and contentious issues, often missed from similar reviews on the field.

We herein present (in a comprehensive yet user-friendly manner) a systematic review of the current literature in a form of question-and-answer. We expect CE readers, of all experience levels, will find this review useful source of further reading and reference. WHICH ARE THE DIFFERENCES AMONG THE CURRENT Cilengitide COMMERCIALLY AVAILABLE CAPSULES? Since 2001, the year of approval by the Food and Drug Administration of the first video capsule with the prophetic, yet slightly unfortunate, brand name mouth-to-anus (M2A?; Given?Imaging, Yoqneam, Israel), a total of more than 2000000 capsules have been ingested worldwide[5]. Furthermore, over the last decade, technology has improved in the field of CE as competition has become quite stiff. At present time, there are 5 small-bowel capsule enteroscopy (SBCE) models in the market worldwide (Table (Table11)[5,6]. Although similar in size and shape, they differ on several technical aspects. Of the 5 SBCE, four are in widespread use, although most of the published literature studies are with PillCam?. Nevertheless, head-to-head trials have showed in the great majority of studies comparable results in terms of DY, image quality and completion rate (Table (Table22)[7-11].

Related posts:

  1. The main outcome was a six-month incidence of recurrent VTE and related death
  2. ZSTK474 authors believe that aurora kinases are important
  3. These success demonstrate that changing personal substituents won
  4. Isobolograms revealed the synergistic outcome for the mix of imatinib in additio
  5. Vincristine leurocristine authors meet the criteria for authorship as recommended
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>